New ISR Report: Enhancing Relationships, Patient Recruitment with Patient Advocacy Groups

New ISR Report: Enhancing Relationships, Patient Recruitment with Patient Advocacy Groups

<0> Industry Standard ResearchKevin Olson, 919-301-0106 </0>

(ISR) today announced the release of a new market research report titled “.” For the report, ISR interviewed senior decision-makers from ten prominent patient advocacy groups to provide never before seen qualitative insight into the current relationships advocacy groups have with the biopharmaceutical industry, as well as best practices for improving those relationships and activates related to clinical trial recruitment.

“Patient advocacy groups are spread across the spectrum regarding how involved they are with the development of new medicines. All respondents posit that clinical trials are the way to move forward, but for various reasons many have yet to delve into playing a role in the clinical trial process,” explained Kevin Olson, CEO of ISR. “ISR’s newest report explores these relationships, offering best practices and proven strategies to broaden partnerships, obtaining support, and where appropriate, recruit trial participants.”

ISR’s report offers “use-cases” and strategies for pharmaceutical and biotechnology organizations looking to broaden recruitment channels for difficult-to-recruit trials and/or optimize communications with advocacy groups.

For more information about this report, please visit ISR’s website:

is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about our off-the-shelf intelligence and custom research offerings, please visit the company’s Web site at , email , or follow us on Twitter .

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.